top of page
Anchor_our_innov
Our
Innovation
Based on the successful discovery of TCR Repertoire bio-markers for breast and ovarian cancer ovarian cancer in human samples,
Clonal seeks to expand this method over a larger cohort of samples.
Our first products are for early detection of two diseases: breast cancer and ovarian cancer.
Anchor_proof
High
accuracy
High
sensitivity
High
specificity
Proof of Concept
We performed validation of these concepts using blood samples from 46 newly diagnosed ovarian cancer patients, which we contrasted with 51 healthy donors. The T-cell repertoires, classified using machine learning, helped us select a subset of TCRs that stratify these two clinical groups
Early detection of ovarian cancer greatly improves the chances of recovery. We demonstrated that the adaptive immune system could be used as a lookout for early physiological events.
01
Study Design
02
Protocol
Assembly
03
Data
Acquisition
04
Computational
Analysis
05
Data
Acquisition
bottom of page